Alphabet-A
GOOGL
Alphabet-C
GOOG
MicroStrategy
MSTR
Tesla
TSLA
Ecopetrol
EC
US Stock MarketDetailed Quotes
CRNX Crinetics
- 57.170
- +0.550+0.97%
Close Dec 10 16:00 ET
- 58.160
- +0.990+1.73%
Pre 06:08 ET
5.30BMarket Cap-15.45P/E (TTM)
58.280High55.960Low557.28KVolume57.060Open56.620Pre Close31.99MTurnover0.61%Turnover RatioLossP/E (Static)92.74MShares62.53052wk High6.36P/B5.23BFloat Cap32.92152wk Low--Dividend TTM91.47MShs Float62.530Historical High--Div YieldTTM4.10%Amplitude10.630Historical Low57.410Avg Price1Lot Size
Crinetics News
JMP Securities Maintains Crinetics(CRNX.US) With Buy Rating, Raises Target Price to $87
LifeSci Capital Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $82
Analysts Conflicted on These Healthcare Names: Lexicon Pharmaceuticals (LXRX), Halozyme (HALO) and Crinetics Pharmaceuticals (CRNX)
LifeSci Capital Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $82
Promising Outlook for Crinetics Pharmaceuticals' Paltusotine in Phase 3 Trial Drives Buy Rating
Citi Maintains Crinetics(CRNX.US) With Buy Rating, Raises Target Price to $74
Crinetics Pharmaceuticals Analyst Ratings
JonesTrading Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $71
Piper Sandler Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $97
Piper Sandler Remains a Buy on Crinetics Pharmaceuticals (CRNX)
Morgan Stanley Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $70
H.C. Wainwright Maintains Crinetics(CRNX.US) With Buy Rating, Raises Target Price to $81
LifeSci Capital Maintains Crinetics(CRNX.US) With Buy Rating, Raises Target Price to $82
Crinetics Pharmaceuticals: Advancing Cancer Treatment With Novel NDC Platform – A Buy Recommendation
LifeSci Capital Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $77
JonesTrading Maintains Crinetics(CRNX.US) With Buy Rating, Raises Target Price to $71
Piper Sandler Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $97
Piper Sandler Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $97
LifeSci Capital Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $77
JMP Securities Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $80
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.